Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
E-mail:
Web: cytokines.ru


  


Year 2017
Number 3

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:

https://pornoseksxxx.com/

Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2016, No. 1

Subscribe for 2018 year

Order this issue

Order PDF of this article

Reviews

Number 1'2016

Use of interferons: immunological and clinical aspects

N.V. Verlan

The review presents an analysis of the current state of the problem of immune system regulation functions, and organizes data on action and biological activity of interferons (IFN) and interferon inducers. As part of the overall body cytokine system, IFN assigned to immunoregulatory molecules that affect all cells of the immune system. Information on pilot studies and clinical observation on pharmacological properties and mechanism of action of IFN and interferon inducers used as antiviral agents is systematized. Indications and contraindications for use of IFN and IFN inducers in viral and non-viral diseases are defined. IFN can play an important role in the correction of immune disorders. However, there are contradictory opinions concerning the IFN adverse effects such as the formation of anti-IFN antibodies (hypersensitivity); dyspepsia; pruritus, rash, dry skin, etc. IFN inducers display not only anti-viral, but also immunocorrective effect that allows to assign them to a new generation of drugs of universal broad-spectrum, with low risk of drug toxicity manifestations. Conclusion. To correct the symptoms of virus-induced processes, the search for new pharmacological targets is necessary. The drug Kagocel, referring to the group of interferon inducers, has high efficiency and good safety profile, which gives reason to recommend it as a first-line therapy for preventing and treating a number of diseases of viral etiology. (Cytokines and Inflammation. 2016. Vol. 15. № 1. P. 12–21.).

Keywords: immunity, interferon, Kagocel, pharmacology, application.

Contents | Next article | Previous article


© 2007-2018 Cytokines and inflammation